Dr. Fernando Camargo is a Principal Investigator at Boston Children's Hospital and a Professor in the Department of Stem Cell and Regenerative Biology at Harvard medical School. His laboratory is interested in studying stem cell biology, Hippo/YAP pathway, and hematopoiesis.
Fernando D. Camargo, Ph.D. studied in the laboratory of Dr. Margaret Goodell for his doctoral work in the Department of Pediatrics at Baylor College of Medicine. In 2005, he became a Whitehead Fellow at the Whitehead Institute for Biomedical Research, where he directed a laboratory focused on the regulation of stem cell proliferation and differentiation and the mechanisms that control tissue size in mammals. In 2009, he became a faculty member in the Stem Cell Program at Boston Children's Hospital and in the Department of Stem Cell and Regenerative Biology at Harvard University. Dr. Camargo studies the crucial differences between the cellular mechanisms that drive unperturbed versus transplant hematopoiesis and how tumor growth is prevented by understanding how organs are formed. His laboratory provided the first evidence that an emerging developmental signaling pathway, the Hippo pathway, is an important regulator of stem cell biology and tissue regeneration in epithelial tissues. More recently his lab developed a novel experimental system in which they can clonally label hematopoietic stem and progenitor cells in situ in the mouse.
Dr. Camargo's work in both the Hippo pathway and hematopoietic stem and progenitor cells has garnered notice and plaudits in recent years. He has received several awards such as the NIH Director's New Innovator, Pew Foundation Scholar Award, the Leukemia and Lymphoma Scholar award, and most recently the Vilcek Award for Creative Promise in Biomedical Science.
Because of his continuous record of innovation and scientific discovery, Dr. Camargo has been the recipient of multiple scientific honors. He is the recipient of the NIH Director’s New Innovator Award, a PEW fellow in the Biomedical Sciences and special fellow of the Leukemia and Lymphoma Society.
Most recently, he has received the Vilcek Prize for Creative Promise in Biomedical Science, the International Society of Stem Cell Research’s Dr. Susan Lim Award for Outstanding Young Investigator, and has been named a Howard Hughes Medical Institute Scholar. In February 2022, Dr. Camargo was named the first Regenerative Biology Endowed Chair, in recognition of his scientific contributions and strong leadership.
Michael Edward Quach